{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:15:38Z","timestamp":1793394938248,"version":"4.5.0"},"reference-count":265,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41582-025-01132-4","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T16:12:03Z","timestamp":1757002323000},"page":"606-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-3133","authenticated-orcid":false,"given":"Ewa A.","family":"Zi\u00f3\u0142kowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2183-068X","authenticated-orcid":false,"given":"Keigo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3467-8488","authenticated-orcid":false,"given":"Patricia I.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6484-0250","authenticated-orcid":false,"given":"Marco","family":"Sardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5559-0832","authenticated-orcid":false,"given":"Mark S.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-4750","authenticated-orcid":false,"given":"Jonathan D.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"1132_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40263-019-00620-8","volume":"33","author":"A Kohlsch\u00fctter","year":"2019","unstructured":"Kohlsch\u00fctter, A., Schulz, A., Bartsch, U. & Storch, S. Current and emerging treatment strategies for neuronal ceroid lipofuscinoses. CNS Drugs 33, 315\u2013325 (2019).","journal-title":"CNS Drugs"},{"key":"1132_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1474-4422(18)30368-5","volume":"18","author":"SE Mole","year":"2019","unstructured":"Mole, S. E. et al. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol. 18, 107\u2013116 (2019).","journal-title":"Lancet Neurol."},{"key":"1132_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41582-019-0138-8","volume":"15","author":"TB Johnson","year":"2019","unstructured":"Johnson, T. B. et al. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat. Rev. Neurol. 15, 161\u2013178 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"1132_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pediatrneurol.2021.04.002","volume":"120","author":"EF Augustine","year":"2021","unstructured":"Augustine, E. F. et al. Management of CLN1 disease: International clinical consensus. Pediatr. Neurol. 120, 38\u201351 (2021).","journal-title":"Pediatr. Neurol."},{"key":"1132_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01813-5","volume":"16","author":"SE Mole","year":"2021","unstructured":"Mole, S. E. et al. Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet J. Rare Dis. 16, 185 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"1132_CR6","first-page":"73","volume":"6","author":"JR Ostergaard","year":"2016","unstructured":"Ostergaard, J. R. Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights. Degener. Neurol. Neuromuscul. Dis. 6, 73\u201383 (2016).","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"1132_CR7","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.bbadis.2012.11.014","volume":"1832","author":"GW Anderson","year":"2013","unstructured":"Anderson, G. W., Goebel, H. H. & Simonati, A. Human pathology in NCL. Biochim. Biophys. Acta 1832, 1807\u20131826 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"1132_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1750-3639.2004.tb00077.x","volume":"14","author":"J Tyynel\u00e4","year":"2004","unstructured":"Tyynel\u00e4, J., Cooper, J. D., Khan, M. N., Shemilt, S. J. & Haltia, M. Hippocampal pathology in the human neuronal ceroid-lipofuscinoses: distinct patterns of storage deposition, neurodegeneration and glial activation. Brain Pathol. 14, 349\u2013357 (2004).","journal-title":"Brain Pathol."},{"key":"1132_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00401-005-0024-x","volume":"111","author":"Y Hachiya","year":"2006","unstructured":"Hachiya, Y. et al. Mechanisms of neurodegeneration in neuronal ceroid-lipofuscinoses. Acta Neuropathol. 111, 168\u2013177 (2006).","journal-title":"Acta Neuropathol."},{"key":"1132_CR10","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.bbadis.2015.05.007","volume":"1852","author":"J Radke","year":"2015","unstructured":"Radke, J., Stenzel, W. & Goebel, H. H. Human NCL neuropathology. Biochim. Biophys. Acta 1852, 2262\u20132266 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"1132_CR11","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s40265-017-0771-8","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham, A. Cerliponase alfa: first global approval. Drugs 77, 1247\u20131249 (2017).","journal-title":"Drugs"},{"key":"1132_CR12","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz, A. et al. CLN2 study group. Study of intraventricular cerliponase alfa for CLN2 disease. N. Engl. J. Med. 378, 1898\u20131907 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1132_CR13","first-page":"386","volume":"23","author":"FE Batten","year":"1903","unstructured":"Batten, F. E. Cerebral degeneration with symmetrical changes in the maculae in two members of a family. Trans. Ophthalmol. Soc. UK 23, 386\u2013390 (1903).","journal-title":"Trans. Ophthalmol. Soc. UK"},{"key":"1132_CR14","first-page":"347","volume":"1","author":"OC Stengel","year":"1826","unstructured":"Stengel, O. C. Beretning om et maerkeligt Sygdomstilfaelde hos fire S\u00f8dskende I N\u00e6rheden af R\u00f6raas. Eyr 1, 347\u2013352 (1826).","journal-title":"Eyr"},{"key":"1132_CR15","first-page":"970","volume":"124","author":"A Brean","year":"2004","unstructured":"Brean, A. An account of a strange instance of disease-Stengel-Batten-Spielmayer-Vogt disease. Tidsskr. Nor. Laegeforen. 124, 970\u2013971 (2004).","journal-title":"Tidsskr. Nor. Laegeforen."},{"key":"1132_CR16","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.bbadis.2012.08.012","volume":"1832","author":"M Haltia","year":"2013","unstructured":"Haltia, M. & Goebel, H. H. The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim. Biophys. Acta 1832, 1795\u201317800 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"1132_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1212\/WNL.0b013e31825f0547","volume":"79","author":"RE Williams","year":"2012","unstructured":"Williams, R. E. & Mole, S. E. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology 79, 183\u2013191 (2012).","journal-title":"Neurology"},{"key":"1132_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1542\/peds.44.4.570","volume":"44","author":"W Zeman","year":"1969","unstructured":"Zeman, W. & Dyken, P. Neuronal ceroid-lipofuscinosis (Batten\u2019s disease): relationship to amaurotic family idiocy? Pediatrics 44, 570\u2013583 (1969).","journal-title":"Pediatrics"},{"key":"1132_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.neurobiolaging.2005.12.006","volume":"27","author":"SS Seehafer","year":"2006","unstructured":"Seehafer, S. S. & Pearce, D. A. You say lipofuscin, we say ceroid: defining autofluorescent storage material. Neurobiol. Aging 27, 576\u2013588 (2006).","journal-title":"Neurobiol. Aging"},{"key":"1132_CR20","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/376584a0","volume":"376","author":"J Vesa","year":"1995","unstructured":"Vesa, J. et al. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 376, 584\u2013587 (1995).","journal-title":"Nature"},{"key":"1132_CR21","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1126\/science.277.5333.1802","volume":"277","author":"DE Sleat","year":"1997","unstructured":"Sleat, D. E. et al. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 277, 1802\u20131805 (1997).","journal-title":"Science"},{"key":"1132_CR22","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/0092-8674(95)90274-0","volume":"82","author":"TJ Lerner","year":"1995","unstructured":"Lerner, T. J. et al. Isolation of a novel gene underlying Batten disease, CLN3. Cell 82, 949\u2013957 (1995).","journal-title":"Cell"},{"key":"1132_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/ana.20187","volume":"56","author":"A Schulz","year":"2004","unstructured":"Schulz, A. et al. Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant. Ann. Neurol. 56, 342\u2013350 (2004).","journal-title":"Ann. Neurol."},{"key":"1132_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/975","volume":"19","author":"M Savukoski","year":"1998","unstructured":"Savukoski, M. et al. CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis. Nat. Genet. 19, 286\u2013288 (1998).","journal-title":"Nat. Genet."},{"key":"1132_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1086\/338708","volume":"70","author":"RB Wheeler","year":"2002","unstructured":"Wheeler, R. B. et al. The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein. Am. J. Hum. Genet. 70, 537\u2013542 (2002).","journal-title":"Am. J. Hum. Genet."},{"key":"1132_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/brain\/awn366","volume":"132","author":"M Kousi","year":"2009","unstructured":"Kousi, M. et al. Mutations in CLN7\/MFSD8 are a common cause of variant late-infantile neuronal ceroid lipofuscinosis. Brain 132, 810\u2013819 (2009).","journal-title":"Brain"},{"key":"1132_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/13868","volume":"23","author":"S Ranta","year":"1999","unstructured":"Ranta, S. et al. The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8. Nat. Genet. 23, 233\u2013236 (1999).","journal-title":"Nat. Genet."},{"key":"1132_CR28","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1093\/brain\/awl107","volume":"129","author":"E Siintola","year":"2006","unstructured":"Siintola, E. et al. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain 129, 1438\u20131445 (2006).","journal-title":"Brain"},{"key":"1132_CR29","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1111\/epi.12632","volume":"55","author":"L Canafoglia","year":"2014","unstructured":"Canafoglia, L. et al. Recurrent generalized seizures, visual loss, and palinopsia as phenotypic features of neuronal ceroid lipofuscinosis due to progranulin gene mutation. Epilepsia 55, e56\u2013e59 (2014).","journal-title":"Epilepsia"},{"key":"1132_CR30","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1093\/hmg\/dds089","volume":"21","author":"J Bras","year":"2012","unstructured":"Bras, J., Verloes, A., Schneider, S. A., Mole, S. E. & Guerreiro, R. J. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum. Mol. Genet. 21, 2646\u20132650 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"1132_CR31","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/hmg\/dds558","volume":"22","author":"KR Smith","year":"2013","unstructured":"Smith, K. R. et al. Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Hum. Mol. Genet. 22, 1417\u20131423 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"1132_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ajhg.2012.05.023","volume":"91","author":"JF Staropoli","year":"2012","unstructured":"Staropoli, J. F. et al. A homozygous mutation in KCTD7 links neuronal ceroid lipofuscinosis to the ubiquitin-proteasome system. Am. J. Hum. Genet. 91, 202\u2013208 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"1132_CR33","unstructured":"Neufeld, E. F. & Muenzer, J. In: The Online Metabolic and Molecular Bases of Inherited Disease (ed. Valle, D. L. et al.) (McGraw Hill, 2019)."},{"key":"1132_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","volume":"4","author":"FM Platt","year":"2018","unstructured":"Platt, F. M., Azzo, A., Davidson, B. L., Neufeld, E. F. & Tifft, C. J. Lysosomal storage diseases. Nat. Rev. Dis. Prim. 4, 27 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1132_CR35","doi-asserted-by":"publisher","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","volume":"50","author":"J Muenzer","year":"2011","unstructured":"Muenzer, J. Overview of the mucopolysaccharidoses. Rheumatol 50, v4\u2013v12 (2011).","journal-title":"Rheumatol"},{"key":"1132_CR36","doi-asserted-by":"publisher","first-page":"100874","DOI":"10.1016\/j.spen.2021.100874","volume":"37","author":"KL McBride","year":"2021","unstructured":"McBride, K. L. & Flanigan, K. M. Update in the mucopolysaccharidoses. Semin. Pediatr. Neurol. 37, 100874 (2021).","journal-title":"Semin. Pediatr. Neurol."},{"key":"1132_CR37","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41556-018-0228-7","volume":"20","author":"A di Ronza","year":"2018","unstructured":"di Ronza, A. et al. CLN8 is an endoplasmic reticulum cargo receptor that regulates lysosome biogenesis. Nat. Cell Biol. 20, 1370\u20131377 (2018).","journal-title":"Nat. Cell Biol."},{"key":"1132_CR38","first-page":"4118","volume":"130","author":"L Bajaj","year":"2020","unstructured":"Bajaj, L. et al. A CLN6-CLN8 complex recruits lysosomal enzymes at the ER for Golgi transfer. J. Clin. Invest. 130, 4118\u20134132 (2020).","journal-title":"J. Clin. Invest."},{"key":"1132_CR39","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012836","volume":"13","author":"G Parenti","year":"2021","unstructured":"Parenti, G., Medina, D. L. & Ballabio, A. The rapidly evolving view of lysosomal storage diseases. EMBO Mol. Med. 13, e12836 (2021).","journal-title":"EMBO Mol. Med."},{"key":"1132_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ajhg.2011.07.003","volume":"89","author":"L Noskov\u00e1","year":"2011","unstructured":"Noskov\u00e1, L. et al. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am. J. Hum. Genet. 89, 241\u2013252 (2011).","journal-title":"Am. J. Hum. Genet."},{"key":"1132_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026741","volume":"6","author":"BA Benitez","year":"2011","unstructured":"Benitez, B. A. et al. Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis. PLoS One 6, e26741 (2011).","journal-title":"PLoS One"},{"key":"1132_CR42","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","volume":"13","author":"MS Sands","year":"2006","unstructured":"Sands, M. S. & Davidson, B. L. Gene therapy for lysosomal storage diseases. Mol. Ther. 13, 839\u2013849 (2006).","journal-title":"Mol. Ther."},{"key":"1132_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1126\/science.169.3941.141","volume":"169","author":"EF Neufeld","year":"1970","unstructured":"Neufeld, E. F. & Fratantoni, J. C. Inborn errors of mucopolysaccharide metabolism. Science 169, 141\u2013146 (1970).","journal-title":"Science"},{"key":"1132_CR44","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1042\/bst0180367","volume":"18","author":"S Kornfeld","year":"1990","unstructured":"Kornfeld, S. Lysosomal enzyme targeting. Biochem. Soc. Trans. 18, 367\u2013374 (1990).","journal-title":"Biochem. Soc. Trans."},{"key":"1132_CR45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev.bi.61.070192.001515","volume":"61","author":"S Kornfeld","year":"1992","unstructured":"Kornfeld, S. Structure and function of the mannose 6-phosphate\/insulinlike growth factor II receptors. Annu. Rev. Biochem. 61, 307\u2013330 (1992).","journal-title":"Annu. Rev. Biochem."},{"key":"1132_CR46","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","volume":"1793","author":"T Braulke","year":"2009","unstructured":"Braulke, T. & Bonifacino, J. S. Sorting of lysosomal proteins. Biochim. Biophys. Acta 1793, 605\u2013614 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"1132_CR47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/mt.2008.9","volume":"16","author":"M Chang","year":"2008","unstructured":"Chang, M. et al. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther. 16, 649\u2013656 (2008).","journal-title":"Mol. Ther."},{"key":"1132_CR48","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1038\/mt.2011.130","volume":"19","author":"S Xu","year":"2011","unstructured":"Xu, S. et al. Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther. 19, 1842\u20131848 (2011).","journal-title":"Mol. Ther."},{"key":"1132_CR49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.omtm.2017.01.004","volume":"4","author":"JA Wiseman","year":"2017","unstructured":"Wiseman, J. A. et al. Chronic enzyme replacement to the brain of a late infantile neuronal ceroid lipofuscinosis mouse has differential effects on phenotypes of disease. Mol. Ther. Methods Clin. Dev. 4, 204\u2013212 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1132_CR50","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/jnr.23423","volume":"92","author":"ML Katz","year":"2014","unstructured":"Katz, M. L. et al. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease). J. Neurosci. Res. 92, 1591\u20131598 (2014).","journal-title":"J. Neurosci. Res."},{"key":"1132_CR51","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ymgme.2014.09.004","volume":"114","author":"BR Vuillemenot","year":"2015","unstructured":"Vuillemenot, B. R. et al. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 114, 281\u2013293 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"1132_CR52","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ymgme.2012.05.009","volume":"107","author":"J Hu","year":"2012","unstructured":"Hu, J. et al. Intravenous high-dose enzyme replacement therapy with recombinant palmitoyl-protein thioesterase reduces visceral lysosomal storage and modestly prolongs survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 107, 213\u2013221 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"1132_CR53","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ymgme.2015.05.005","volume":"116","author":"JY Lu","year":"2015","unstructured":"Lu, J. Y. et al. Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 116, 98\u2013105 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"1132_CR54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163107","volume":"132","author":"HR Nelvagal","year":"2022","unstructured":"Nelvagal, H. R. et al. Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep. J. Clin. Invest. 132, e163107 (2022).","journal-title":"J. Clin. Invest."},{"key":"1132_CR55","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.nbd.2004.03.005","volume":"16","author":"MA Griffey","year":"2004","unstructured":"Griffey, M. A. et al. Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16, 360\u2013369 (2004).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR56","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ymthe.2005.04.018","volume":"12","author":"M Griffey","year":"2005","unstructured":"Griffey, M., Macauley, S. L., Ogilvie, J. M. & Sands, M. S. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol. Ther. 12, 413\u2013421 (2005).","journal-title":"Mol. Ther."},{"key":"1132_CR57","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ymthe.2005.11.008","volume":"13","author":"MA Griffey","year":"2006","unstructured":"Griffey, M. A. et al. CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol. Ther. 13, 538\u2013547 (2006).","journal-title":"Mol. Ther."},{"key":"1132_CR58","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.23545","volume":"71","author":"SL Macauley","year":"2012","unstructured":"Macauley, S. L. et al. Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis. Ann. Neurol. 71, 797\u2013804 (2012).","journal-title":"Ann. Neurol."},{"key":"1132_CR59","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10545-011-9446-x","volume":"35","author":"MS Roberts","year":"2012","unstructured":"Roberts, M. S. et al. Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis. J. Inherit. Metab. Dis. 35, 847\u2013857 (2012).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1132_CR60","doi-asserted-by":"publisher","first-page":"13077","DOI":"10.1523\/JNEUROSCI.2518-14.2014","volume":"34","author":"SL Macauley","year":"2014","unstructured":"Macauley, S. L. et al. An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis. J. Neurosci. 34, 13077\u201313082 (2014).","journal-title":"J. Neurosci."},{"key":"1132_CR61","doi-asserted-by":"publisher","first-page":"E5920","DOI":"10.1073\/pnas.1701832114","volume":"114","author":"C Shyng","year":"2017","unstructured":"Shyng, C. et al. Synergistic effects of treating the spinal cord and brain in CLN1 disease. Proc. Natl Acad. Sci. USA 114, E5920\u2013E5929 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1132_CR62","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1523\/JNEUROSCI.2676-05.2006","volume":"26","author":"MA Passini","year":"2006","unstructured":"Passini, M. A. et al. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J. Neurosci. 26, 1334\u20131342 (2006).","journal-title":"J. Neurosci."},{"key":"1132_CR63","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/sj.gt.3302549","volume":"12","author":"D Sondhi","year":"2005","unstructured":"Sondhi, D. et al. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther. 12, 1618\u20131632 (2005).","journal-title":"Gene Ther."},{"key":"1132_CR64","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/sj.mt.6300249","volume":"15","author":"MA Cabrera-Salazar","year":"2007","unstructured":"Cabrera-Salazar, M. A. et al. Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile Batten disease. Mol. Ther. 15, 1782\u20131788 (2007).","journal-title":"Mol. Ther."},{"key":"1132_CR65","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.expneurol.2008.04.022","volume":"213","author":"D Sondhi","year":"2008","unstructured":"Sondhi, D. et al. Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. Exp. Neurol. 213, 18\u201327 (2008).","journal-title":"Exp. Neurol."},{"key":"1132_CR66","doi-asserted-by":"publisher","first-page":"313ra180","DOI":"10.1126\/scitranslmed.aac6191","volume":"7","author":"ML Katz","year":"2015","unstructured":"Katz, M. L. et al. AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease. Sci. Transl. Med. 7, 313ra180 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1132_CR67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165908","volume":"133","author":"K Takahashi","year":"2023","unstructured":"Takahashi, K. et al. Gene therapy ameliorates spontaneous seizures associated with cortical neuron loss in a Cln2R207X mouse model. J. Clin. Invest. 133, e165908 (2023).","journal-title":"J. Clin. Invest."},{"key":"1132_CR68","doi-asserted-by":"publisher","first-page":"eadr2531","DOI":"10.1126\/scitranslmed.adr2531","volume":"17","author":"L Tecedor","year":"2025","unstructured":"Tecedor, L. et al. An AAV variant selected through NHP screens robustly transduces the brain and drives secreted protein expression in NHPs and mice. Sci. Transl. Med. 17, eadr2531 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1132_CR69","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.ymthe.2018.07.015","volume":"26","author":"NL Mitchell","year":"2018","unstructured":"Mitchell, N. L. et al. Longitudinal in vivo monitoring of the CNS demonstrates the efficacy of gene therapy in a sheep model of CLN5 Batten disease. Mol. Ther. 26, 2366\u20132378 (2018).","journal-title":"Mol. Ther."},{"key":"1132_CR70","doi-asserted-by":"publisher","first-page":"1212228","DOI":"10.3389\/fgene.2023.1212228","volume":"14","author":"NL Mitchell","year":"2023","unstructured":"Mitchell, N. L. et al. Long-term safety and dose escalation of intracerebroventricular CLN5 gene therapy in sheep supports clinical translation for CLN5 Batten disease. Front. Genet. 14, 1212228 (2023).","journal-title":"Front. Genet."},{"key":"1132_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.70431","volume":"15","author":"SJ Murray","year":"2025","unstructured":"Murray, S. J. et al. Magnetic resonance imaging as a readout of CLN5 gene therapy efficacy in sheep. Brain Behav. 15, e70431 (2025).","journal-title":"Brain Behav."},{"key":"1132_CR72","doi-asserted-by":"publisher","first-page":"108600","DOI":"10.1016\/j.exer.2021.108600","volume":"207","author":"SJ Murray","year":"2021","unstructured":"Murray, S. J. et al. Intravitreal gene therapy protects against retinal dysfunction and degeneration in sheep with CLN5 Batten disease. Exp. Eye Res. 207, 108600 (2021).","journal-title":"Exp. Eye Res."},{"key":"1132_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1212235","volume":"14","author":"SJ Murray","year":"2023","unstructured":"Murray, S. J. et al. Efficacy of dual intracerebroventricular and intravitreal CLN5 gene therapy in sheep prompts the first clinical trial to treat CLN5 Batten disease. Front. Pharmacol. 14, 1212235 (2023).","journal-title":"Front. Pharmacol."},{"key":"1132_CR74","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1089\/hum.2012.253","volume":"25","author":"D Sondhi","year":"2014","unstructured":"Sondhi, D. et al. Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene. Hum. Gene Ther. 25, 223\u2013239 (2014).","journal-title":"Hum. Gene Ther."},{"key":"1132_CR75","doi-asserted-by":"publisher","first-page":"9669","DOI":"10.1523\/JNEUROSCI.1635-16.2016","volume":"36","author":"ME Bosch","year":"2016","unstructured":"Bosch, M. E. et al. Self-complementary AAV9 gene delivery partially corrects pathology associated with juvenile neuronal ceroid lipofuscinosis (CLN3). J. Neurosci. 36, 9669\u20139682 (2016).","journal-title":"J. Neurosci."},{"key":"1132_CR76","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1089\/hum.2020.038","volume":"31","author":"Kleine","year":"2020","unstructured":"Kleine et al. Gene therapy targeting the inner retina rescues the retinal phenotype in a mouse model of CLN3 Batten disease. Hum. Gene Ther. 31, 709\u2013718 (2020).","journal-title":"Hum. Gene Ther."},{"key":"1132_CR77","doi-asserted-by":"publisher","first-page":"1118649","DOI":"10.3389\/fgene.2023.1118649","volume":"14","author":"TB Johnson","year":"2023","unstructured":"Johnson, T. B. et al. Early postnatal administration of an AAV9 gene therapy is safe and efficacious in CLN3 disease. Front. Genet. 14, 1118649 (2023).","journal-title":"Front. Genet."},{"key":"1132_CR78","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s40478-025-02059-z","volume":"13","author":"EA Zi\u00f3\u0142kowska","year":"2025","unstructured":"Zi\u00f3\u0142kowska, E. A. et al. Gene therapy ameliorates neuromuscular pathology in CLN3 disease. Acta Neuropathol. Commun. 13, 160 (2025).","journal-title":"Acta Neuropathol. Commun."},{"key":"1132_CR79","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.ymthe.2018.02.027","volume":"26","author":"Kleine","year":"2018","unstructured":"Kleine et al. Prevention of photoreceptor cell loss in a Cln6nclf mouse model of Batten disease requires CLN6 gene transfer to bipolar cells. Mol. Ther. 26, 1343\u20131353 (2018).","journal-title":"Mol. Ther."},{"key":"1132_CR80","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1093\/hmg\/ddz210","volume":"28","author":"Kleine","year":"2019","unstructured":"Kleine et al. Neonatal brain-directed gene therapy rescues a mouse model of neurodegenerative CLN6 Batten disease. Hum. Mol. Genet. 28, 3867\u20133879 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"1132_CR81","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.ymthe.2019.06.015","volume":"27","author":"JT Cain","year":"2019","unstructured":"Cain, J. T. et al. Gene therapy corrects brain and behavioral pathologies in CLN6-Batten disease. Mol. Ther. 27, 1836\u20131847 (2019).","journal-title":"Mol. Ther."},{"key":"1132_CR82","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.omtm.2020.12.014","volume":"20","author":"KA White","year":"2021","unstructured":"White, K. A. et al. Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease mice. Mol. Ther. Methods Clin. Dev. 20, 497\u2013507 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1132_CR83","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146286","volume":"132","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. AAV9\/MFSD8 gene therapy is effective in preclinical models of neuronal ceroid lipofuscinosis type 7 disease. J. Clin. Invest. 132, e146286 (2022).","journal-title":"J. Clin. Invest."},{"key":"1132_CR84","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1126\/science.1142658","volume":"317","author":"A Donsante","year":"2007","unstructured":"Donsante, A. et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317, 477 (2007).","journal-title":"Science"},{"key":"1132_CR85","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","volume":"30","author":"DE Sabatino","year":"2022","unstructured":"Sabatino, D. E. et al. Evaluating the state of the science for adeno-associated virus integration: an integrated perspective. Mol. Ther. 30, 2646\u20132663 (2022).","journal-title":"Mol. Ther."},{"key":"1132_CR86","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644\u20131652 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1132_CR87","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/s41591-020-0986-1","volume":"26","author":"JL Centa","year":"2020","unstructured":"Centa, J. L. et al. Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten disease. Nat. Med. 26, 1444\u20131451 (2020).","journal-title":"Nat. Med."},{"key":"1132_CR88","unstructured":"Zebronkysen. Fore Batten Foundation https:\/\/www.forebatten.org\/zebronkysen (2024)."},{"key":"1132_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0844-0","volume":"13","author":"M Pineda","year":"2018","unstructured":"Pineda, M., Walterfang, M. & Patterson, M. C. Miglustat in Niemann-Pick disease type C patients: a review. Orphanet J. Rare Dis. 13, 140 (2018).","journal-title":"Orphanet J. Rare Dis."},{"key":"1132_CR90","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05174039 (2024)."},{"key":"1132_CR91","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.1174447","volume":"325","author":"M Sardiello","year":"2009","unstructured":"Sardiello, M. et al. A gene network regulating lysosomal biogenesis and function. Science 325, 473\u2013477 (2009).","journal-title":"Science"},{"key":"1132_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14338","volume":"8","author":"M Palmieri","year":"2017","unstructured":"Palmieri, M. et al. mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat. Commun. 8, 14338 (2017).","journal-title":"Nat. Commun."},{"key":"1132_CR93","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1080\/15548627.2018.1474313","volume":"14","author":"P Lotfi","year":"2018","unstructured":"Lotfi, P. et al. Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency. Autophagy 14, 1419\u20131434 (2018).","journal-title":"Autophagy"},{"key":"1132_CR94","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013742","volume":"13","author":"C Soldati","year":"2021","unstructured":"Soldati, C. et al. Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype. EMBO Mol. Med. 13, e13742 (2021).","journal-title":"EMBO Mol. Med."},{"key":"1132_CR95","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jneuroim.2010.08.024","volume":"230","author":"SS Seehafer","year":"2011","unstructured":"Seehafer, S. S. et al. Immunosuppression alters disease severity in juvenile Batten disease mice. J. Neuroimmunol. 230, 169\u2013172 (2011).","journal-title":"J. Neuroimmunol."},{"key":"1132_CR96","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/j.ymthe.2017.04.021","volume":"25","author":"J Groh","year":"2017","unstructured":"Groh, J., Berve, K. & Martini, R. Fingolimod and teriflunomide attenuate neurodegeneration in mouse models of neuronal ceroid lipofuscinosis. Mol. Ther. 25, 1889\u20131899 (2017).","journal-title":"Mol. Ther."},{"key":"1132_CR97","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3389\/fneur.2019.00963","volume":"10","author":"MA Tarczyluk-Wells","year":"2019","unstructured":"Tarczyluk-Wells, M. A. et al. Combined anti-inflammatory and neuroprotective treatments have the potential to impact disease phenotypes in Cln3 -\/- mice. Front. Neurol. 10, 963 (2019).","journal-title":"Front. Neurol."},{"key":"1132_CR98","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.neuropharm.2010.10.010","volume":"60","author":"AD Kov\u00e1cs","year":"2011","unstructured":"Kov\u00e1cs, A. D. et al. Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease. Neuropharmacology 60, 405\u2013409 (2011).","journal-title":"Neuropharmacology"},{"key":"1132_CR99","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.neuropharm.2012.05.040","volume":"63","author":"AD Kov\u00e1cs","year":"2012","unstructured":"Kov\u00e1cs, A. D. et al. Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease. Neuropharmacology 63, 769\u2013775 (2012).","journal-title":"Neuropharmacology"},{"key":"1132_CR100","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/ana.24815","volume":"80","author":"A Aldrich","year":"2016","unstructured":"Aldrich, A. et al. Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3). Ann. Neurol. 80, 909\u2013923 (2016).","journal-title":"Ann. Neurol."},{"key":"1132_CR101","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/jnc.13987","volume":"141","author":"A Ghosh","year":"2017","unstructured":"Ghosh, A., Rangasamy, S. B., Modi, K. K. & Pahan, K. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J. Neurochem. 141, 423\u2013435 (2017).","journal-title":"J. Neurochem."},{"key":"1132_CR102","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1038\/nn.3526","volume":"16","author":"C Sarkar","year":"2013","unstructured":"Sarkar, C. et al. Neuroprotection and lifespan extension in Ppt1(-\/-) mice by NtBuHA: therapeutic implications for INCL. Nat. Neurosci. 16, 1608\u20131617 (2013).","journal-title":"Nat. Neurosci."},{"key":"1132_CR103","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S1474-4422(14)70142-5","volume":"13","author":"SW Levin","year":"2014","unstructured":"Levin, S. W. et al. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study. Lancet Neurol. 13, 777\u2013787 (2014).","journal-title":"Lancet Neurol."},{"key":"1132_CR104","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","volume":"2","author":"M Nickel","year":"2018","unstructured":"Nickel, M. et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational Cohort study. Lancet Child Adolesc. Health 2, 582\u2013590 (2018).","journal-title":"Lancet Child Adolesc. Health"},{"key":"1132_CR105","doi-asserted-by":"publisher","first-page":"1516026","DOI":"10.3389\/fneur.2025.1516026","volume":"16","author":"A Schulz","year":"2025","unstructured":"Schulz, A. et al. Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa. Front. Neurol. 16, 1516026 (2025).","journal-title":"Front. Neurol."},{"key":"1132_CR106","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(23)00384-8","volume":"23","author":"A Schulz","year":"2024","unstructured":"Schulz, A. et al. Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study. Lancet Neurol. 23, 60\u201370 (2024).","journal-title":"Lancet Neurol."},{"key":"1132_CR107","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3174\/ajnr.A8408","volume":"45","author":"P Gaur","year":"2024","unstructured":"Gaur, P. et al. Enzyme replacement therapy for CLN2 disease: MRI volumetry shows significantly slower volume loss compared with a natural history cohort. AJNR Am. J. Neuroradiol. 45, 1791\u20131797 (2024).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"1132_CR108","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/0883073821989154","volume":"36","author":"C Schwering","year":"2021","unstructured":"Schwering, C. et al. Development of the \u201cHamburg best practice guidelines for ICV-enzyme replacement therapy (ERT) in CLN2 disease\u201d based on 6 years treatment experience in 48 patients. J. Child Neurol. 36, 635\u2013641 (2021).","journal-title":"J. Child Neurol."},{"key":"1132_CR109","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1055\/s-0042-1750729","volume":"53","author":"C Schwering","year":"2022","unstructured":"Schwering, C. et al. Therapeutic management of COVID-19 in a pediatric patient with neurodegenerative CLN2 disease and ICV-enzyme replacement therapy: a case report. Neuropediatrics 53, 381\u2013384 (2022).","journal-title":"Neuropediatrics"},{"key":"1132_CR110","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1136\/bjo-2022-321260","volume":"107","author":"S Dulz","year":"2023","unstructured":"Dulz, S. et al. Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease). Br. J. Ophthalmol. 107, 1478\u20131483 (2023).","journal-title":"Br. J. Ophthalmol."},{"key":"1132_CR111","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05152914 (2024)."},{"key":"1132_CR112","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05791864 (2023)."},{"key":"1132_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-018-1861-8","volume":"136","author":"DH Paushter","year":"2018","unstructured":"Paushter, D. H. et al. The lysosomal function of progranulin, a guardian against neurodegeneration. Acta Neuropathol. 136, 1\u201317 (2018).","journal-title":"Acta Neuropathol."},{"key":"1132_CR114","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.gendis.2017.05.001","volume":"4","author":"J Jian","year":"2017","unstructured":"Jian, J., Hettinghouse, A. & Liu, C. J. Progranulin acts as a shared chaperone and regulates multiple lysosomal enzymes. Genes Dis. 4, 125\u2013126 (2017).","journal-title":"Genes Dis."},{"key":"1132_CR115","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/nature05016","volume":"442","author":"M Baker","year":"2006","unstructured":"Baker, M. et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916\u2013919 (2006).","journal-title":"Nature"},{"key":"1132_CR116","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41586-022-05221-y","volume":"609","author":"NN Laqtom","year":"2022","unstructured":"Laqtom, N. N. et al. CLN3 is required for the clearance of glycerophosphodiesters from lysosomes. Nature 609, 1005\u20131011 (2022).","journal-title":"Nature"},{"key":"1132_CR117","doi-asserted-by":"publisher","DOI":"10.1172\/JCI183592","volume":"135","author":"D Saarela","year":"2024","unstructured":"Saarela, D. et al. Tagless LysoIP for immunoaffinity enrichment of native lysosomes from clinical samples. J. Clin. Invest. 135, e183592 (2024).","journal-title":"J. Clin. Invest."},{"key":"1132_CR118","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.molcel.2024.02.006","volume":"84","author":"K Nyame","year":"2024","unstructured":"Nyame, K. et al. Glycerophosphodiesters inhibit lysosomal phospholipid catabolism in Batten disease. Mol. Cell. 84, 1354\u20131364.e9 (2024).","journal-title":"Mol. Cell."},{"key":"1132_CR119","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1126\/science.adg9288","volume":"381","author":"UN Medoh","year":"2023","unstructured":"Medoh, U. N. et al. The Batten disease gene product CLN5 is the lysosomal bis(monoacylglycero)phosphate synthase. Science 381, 1182\u20131189 (2023).","journal-title":"Science"},{"key":"1132_CR120","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/hmg\/ddy076","volume":"27","author":"T Danyukova","year":"2018","unstructured":"Danyukova, T. et al. Loss of CLN7 results in depletion of soluble lysosomal proteins and impaired mTOR reactivation. Hum. Mol. Genet. 27, 1711\u20131722 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"1132_CR121","doi-asserted-by":"publisher","first-page":"109572","DOI":"10.1016\/j.cellsig.2020.109572","volume":"70","author":"RJ Huber","year":"2020","unstructured":"Huber, R. J., Mathavarajah, S. & Yap, S. Q. Mfsd8 localizes to endocytic compartments and influences the secretion of Cln5 and cathepsin D in dictyostelium. Cell Signal. 70, 109572 (2020).","journal-title":"Cell Signal."},{"key":"1132_CR122","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/boc.202100052","volume":"114","author":"M Jansen","year":"2022","unstructured":"Jansen, M. & Beaumelle, B. How palmitoylation affects trafficking and signaling of membrane receptors. Biol. Cell. 114, 61\u201372 (2022).","journal-title":"Biol. Cell."},{"key":"1132_CR123","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1002\/jcp.30122","volume":"236","author":"J Jin","year":"2021","unstructured":"Jin, J., Zhi, X., Wang, X. & Meng, D. Protein palmitoylation and its pathophysiological relevance. J. Cell Physiol. 236, 3220\u20133233 (2021).","journal-title":"J. Cell Physiol."},{"key":"1132_CR124","doi-asserted-by":"publisher","first-page":"1166125","DOI":"10.3389\/fphys.2023.1166125","volume":"14","author":"F Ramzan","year":"2023","unstructured":"Ramzan, F., Abrar, F., Mishra, G. G., Qi Liao, L. M. & Martin, D. D. O. Lost in traffic: consequences of altered palmitoylation in neurodegeneration. Front. Physiol. 14, 1166125 (2023).","journal-title":"Front. Physiol."},{"key":"1132_CR125","doi-asserted-by":"publisher","first-page":"NS20210005","DOI":"10.1042\/NS20210005","volume":"5","author":"AA Petropavlovskiy","year":"2021","unstructured":"Petropavlovskiy, A. A., Kogut, J. A., Leekha, A., Townsend, C. A. & Sanders, S. S. A sticky situation: regulation and function of protein palmitoylation with a spotlight on the axon and axon initial segment. Neuronal Signal. 5, NS20210005 (2021).","journal-title":"Neuronal Signal."},{"key":"1132_CR126","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bph.15050","volume":"178","author":"T Hayashi","year":"2021","unstructured":"Hayashi, T. Post-translational palmitoylation of ionotropic glutamate receptors in excitatory synaptic functions. Br. J. Pharmacol. 178, 784\u2013797 (2021).","journal-title":"Br. J. Pharmacol."},{"key":"1132_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-03206-1","volume":"14","author":"J Tong","year":"2024","unstructured":"Tong, J. et al. GABAAR-PPT1 palmitoylation homeostasis controls synaptic transmission and circuitry oscillation. Transl. Psychiatry 14, 488 (2024).","journal-title":"Transl. Psychiatry"},{"key":"1132_CR128","doi-asserted-by":"publisher","first-page":"106890","DOI":"10.1016\/j.nbd.2025.106890","volume":"209","author":"N Plavelil","year":"2025","unstructured":"Plavelil, N. et al. Defective anterograde protein-trafficking contributes to endoplasmic reticulum-stress in a CLN1 disease model. Neurobiol. Dis. 209, 106890 (2025).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14612","volume":"8","author":"MB Bagh","year":"2017","unstructured":"Bagh, M. B. et al. Misrouting of v-ATPase subunit V0a1 dysregulates lysosomal acidification in a neurodegenerative lysosomal storage disease model. Nat. Commun. 8, 14612 (2017).","journal-title":"Nat. Commun."},{"key":"1132_CR130","doi-asserted-by":"publisher","first-page":"105641","DOI":"10.1016\/j.jbc.2024.105641","volume":"300","author":"MB Bagh","year":"2024","unstructured":"Bagh, M. B. et al. Disruption of lysosomal nutrient sensing scaffold contributes to pathogenesis of a fatal neurodegenerative lysosomal storage disease. J. Biol. Chem. 300, 105641 (2024).","journal-title":"J. Biol. Chem."},{"key":"1132_CR131","doi-asserted-by":"publisher","first-page":"eadr5703","DOI":"10.1126\/sciadv.adr5703","volume":"11","author":"AP Appu","year":"2025","unstructured":"Appu, A. P. et al. Niemann Pick C1 mistargeting disrupts lysosomal cholesterol homeostasis contributing to neurodegeneration in a Batten disease model. Sci. Adv. 11, eadr5703 (2025).","journal-title":"Sci. Adv."},{"key":"1132_CR132","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1042\/BCJ20230319","volume":"481","author":"E Barker","year":"2024","unstructured":"Barker, E. et al. Proximity labelling reveals effects of disease-causing mutation on the DNAJC5\/cysteine string protein \u03b1 interactome. Biochem. J. 481, 141\u2013160 (2024).","journal-title":"Biochem. J."},{"key":"1132_CR133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001590","author":"EL Gorenberg","year":"2022","unstructured":"Gorenberg, E. L. et al. Identification of substrates of palmitoyl protein thioesterase 1 highlights roles of depalmitoylation in disulfide bond formation and synaptic function. PLoS Biol. https:\/\/doi.org\/10.1371\/journal.pbio.3001590 (2022).","journal-title":"PLoS Biol."},{"key":"1132_CR134","doi-asserted-by":"publisher","first-page":"98","DOI":"10.7555\/JBR.36.20220001","volume":"36","author":"T Dang","year":"2022","unstructured":"Dang, T. et al. ATP13A2 protects dopaminergic neurons in Parkinson\u2019s disease: from biology to pathology. J. Biomed. Res. 36, 98\u2013108 (2022).","journal-title":"J. Biomed. Res."},{"key":"1132_CR135","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41586-020-1968-7","volume":"578","author":"S van Veen","year":"2020","unstructured":"van Veen, S. et al. ATP13A2 deficiency disrupts lysosomal polyamine export. Nature 578, 419\u2013424 (2020).","journal-title":"Nature"},{"key":"1132_CR136","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41421-023-00533-3","volume":"9","author":"J Sharma","year":"2023","unstructured":"Sharma, J. et al. Calpain activity is negatively regulated by a KCTD7-Cullin-3 complex via non-degradative ubiquitination. Cell Discov. 9, 32 (2023).","journal-title":"Cell Discov."},{"key":"1132_CR137","doi-asserted-by":"publisher","first-page":"eabm5578","DOI":"10.1126\/sciadv.abm5578","volume":"8","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. KCTD7 mutations impair the trafficking of lysosomal enzymes through CLN5 accumulation to cause neuronal ceroid lipofuscinoses. Sci. Adv. 8, eabm5578 (2022).","journal-title":"Sci. Adv."},{"key":"1132_CR138","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.bbadis.2013.05.014","volume":"1832","author":"DN Palmer","year":"2013","unstructured":"Palmer, D. N., Barry, L. A., Tyynel\u00e4, J. & Cooper, J. D. NCL disease mechanisms. Biochim. Biophys. Acta 1832, 1882\u20131893 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"1132_CR139","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1016\/j.bbadis.2015.05.014","volume":"1852","author":"JD Cooper","year":"2015","unstructured":"Cooper, J. D., Tarczyluk, M. A. & Nelvagal, H. R. Towards a new understanding of NCL pathogenesis. Biochim. Biophys. Acta 1852, 2256\u20132261 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"1132_CR140","doi-asserted-by":"publisher","first-page":"165570","DOI":"10.1016\/j.bbadis.2019.165570","volume":"1866","author":"HR Nelvagal","year":"2020","unstructured":"Nelvagal, H. R., Lange, J., Takahashi, K., Tarczyluk-Wells, M. A. & Cooper, J. D. Pathomechanisms in the neuronal ceroid lipofuscinoses. Biochim. Biophys. Acta Mol. Basis Dis. 1866, 165570 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1132_CR141","doi-asserted-by":"publisher","first-page":"886567","DOI":"10.3389\/fneur.2022.886567","volume":"13","author":"K Takahashi","year":"2022","unstructured":"Takahashi, K., Nelvagal, H. R., Lange, J. & Cooper, J. D. Glial dysfunction and its contribution to the pathogenesis of the neuronal ceroid lipofuscinoses. Front. Neurol. 13, 886567 (2022).","journal-title":"Front. Neurol."},{"key":"1132_CR142","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1523\/JNEUROSCI.19-07-02556.1999","volume":"19","author":"JD Cooper","year":"1999","unstructured":"Cooper, J. D., Messer, A., Feng, A. K., Chua-Couzens, J. & Mobley, W. C. Apparent loss and hypertrophy of interneurons in a mouse model of neuronal ceroid lipofuscinosis: evidence for partial response to insulin-like growth factor-1 treatment. J. Neurosci. 19, 2556\u20132567 (1999).","journal-title":"J. Neurosci."},{"key":"1132_CR143","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/hmg\/11.12.1421","volume":"11","author":"S Chattopadhyay","year":"2002","unstructured":"Chattopadhyay, S. et al. An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum. Mol. Genet. 11, 1421\u20131431 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"1132_CR144","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.brainres.2004.07.030","volume":"1023","author":"CC Pontikis","year":"2004","unstructured":"Pontikis, C. C. et al. Late onset neurodegeneration in the Cln3-\/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res. 1023, 231\u2013242 (2004).","journal-title":"Brain Res."},{"key":"1132_CR145","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/hmg\/ddh312","volume":"13","author":"O Kopra","year":"2004","unstructured":"Kopra, O. et al. A mouse model for Finnish variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology associated with early aging. Hum. Mol. Genet. 13, 2893\u20132906 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"1132_CR146","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.nbd.2005.05.018","volume":"20","author":"CC Pontikis","year":"2005","unstructured":"Pontikis, C. C., Cotman, S. L., MacDonald, M. E. & Cooper, J. D. Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7\/8 knock-in mouse model of Batten disease. Neurobiol. Dis. 20, 823\u2013836 (2005).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR147","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.nbd.2006.09.001","volume":"25","author":"C Kielar","year":"2007","unstructured":"Kielar, C. et al. Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 25, 150\u2013162 (2007).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR148","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.nbd.2008.06.004","volume":"32","author":"MJ Oswald","year":"2008","unstructured":"Oswald, M. J., Palmer, D. N., Kay, G. W., Barwell, K. J. & Cooper, J. D. Location and connectivity determine GABAergic interneuron survival in the brains of south Hampshire sheep with CLN6 neuronal ceroid lipofuscinosis. Neurobiol. Dis. 32, 50\u201365 (2008).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR149","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/nen.0b013e31815f3899","volume":"67","author":"S Partanen","year":"2008","unstructured":"Partanen, S. et al. Synaptic changes in the thalamocortical system of cathepsin D-deficient mice: a model of human congenital neuronal ceroid-lipofuscinosis. J. Neuropathol. Exp. Neurol. 67, 16\u201329 (2008).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1132_CR150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078694","volume":"8","author":"JP Morgan","year":"2013","unstructured":"Morgan, J. P. et al. A murine model of variant late infantile ceroid lipofuscinosis recapitulates behavioral and pathological phenotypes of human disease. PLoS One 8, e78694 (2013).","journal-title":"PLoS One"},{"key":"1132_CR151","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1093\/hmg\/ddz165","volume":"28","author":"Y Singh","year":"2019","unstructured":"Singh, Y. et al. Loss of Cln5 leads to altered Gad1 expression and deficits in interneuron development in mice. Hum. Mol. Genet. 28, 3309\u20133322 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"1132_CR152","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.184487","author":"K Takahashi","year":"2025","unstructured":"Takahashi, K. et al. GABAergic interneurons contribute to the fatal seizure phenotype of CLN2 disease mice. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.184487 (2025).","journal-title":"JCI Insight"},{"key":"1132_CR153","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.expneurol.2009.01.022","volume":"217","author":"SL Macauley","year":"2009","unstructured":"Macauley, S. L. et al. Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse. Exp. Neurol. 217, 124\u2013135 (2009).","journal-title":"Exp. Neurol."},{"key":"1132_CR154","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/brain\/awt020","volume":"136","author":"J Groh","year":"2013","unstructured":"Groh, J. et al. Immune cells perturb axons and impair neuronal survival in a mouse model of infantile neuronal ceroid lipofuscinosis. Brain 136, 1083\u20131101 (2013).","journal-title":"Brain"},{"key":"1132_CR155","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.nbd.2004.02.010","volume":"16","author":"E Bible","year":"2004","unstructured":"Bible, E., Gupta, P., Hofmann, S. L. & Cooper, J. D. Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16, 346\u2013359 (2004).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR156","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.brainres.2009.02.009","volume":"1266","author":"JM Weimer","year":"2009","unstructured":"Weimer, J. M. et al. Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis. Brain Res. 1266, 93\u2013107 (2009).","journal-title":"Brain Res."},{"key":"1132_CR157","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.brainres.2007.05.018","volume":"1162","author":"JM Weimer","year":"2007","unstructured":"Weimer, J. M. et al. Alterations in striatal dopamine catabolism precede loss of substantia nigra neurons in a mouse model of juvenile neuronal ceroid lipofuscinosis. Brain Res. 1162, 98\u2013112 (2007).","journal-title":"Brain Res."},{"key":"1132_CR158","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.nbd.2005.11.008","volume":"22","author":"JM Weimer","year":"2006","unstructured":"Weimer, J. M. et al. Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiol. Dis. 22, 284\u2013293 (2006).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR159","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/nan.12658","volume":"47","author":"HR Nelvagal","year":"2021","unstructured":"Nelvagal, H. R., Dearborn, J. T., Ostergaard, J. R., Sands, M. S. & Cooper, J. D. Spinal manifestations of CLN1 disease start during the early postnatal period. Neuropathol. Appl. Neurobiol. 47, 251\u2013267 (2021).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"1132_CR160","doi-asserted-by":"publisher","first-page":"1061363","DOI":"10.3389\/fneur.2022.1061363","volume":"11","author":"JR Ostergaard","year":"2022","unstructured":"Ostergaard, J. R., Nelvagal, H. R. & Cooper, J. D. Top-down and bottom-up propagation of disease in the neuronal ceroid lipofuscinoses. Front. Neurol. 11, 1061363 (2022).","journal-title":"Front. Neurol."},{"key":"1132_CR161","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s40478-019-0871-7","volume":"30","author":"G Gomez-Giro","year":"2019","unstructured":"Gomez-Giro, G. et al. Synapse alterations precede neuronal damage and storage pathology in a human cerebral organoid model of CLN3-juvenile neuronal ceroid lipofuscinosis. Acta Neuropathol. Commun. 30, 222 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"1132_CR162","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1016\/j.ymthe.2022.03.025","volume":"6","author":"RC Ahrens-Nicklas","year":"2022","unstructured":"Ahrens-Nicklas, R. C. et al. Neuronal genetic rescue normalizes brain network dynamics in a lysosomal storage disorder despite persistent storage accumulation. Mol. Ther. 6, 2464\u20132473 (2022).","journal-title":"Mol. Ther."},{"key":"1132_CR163","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40478-018-0575-4","volume":"6","author":"J Lange","year":"2018","unstructured":"Lange, J. et al. Compromised astrocyte function and survival negatively impact neurons in infantile neuronal ceroid lipofuscinosis. Acta Neuropathol. Commun. 6, 74 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"1132_CR164","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40478-017-0476-y","volume":"5","author":"L Parviainen","year":"2017","unstructured":"Parviainen, L. et al. Glial cells are functionally impaired in juvenile neuronal ceroid lipofuscinosis and detrimental to neurons. Acta Neuropathol. Commun. 5, 74 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"1132_CR165","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/jnc.14545","volume":"148","author":"ME Bosch","year":"2019","unstructured":"Bosch, M. E. & Kielian, T. Astrocytes in juvenile neuronal ceroid lipofuscinosis (CLN3) display metabolic and calcium signaling abnormalities. J. Neurochem. 148, 612\u2013624 (2019).","journal-title":"J. Neurochem."},{"key":"1132_CR166","doi-asserted-by":"publisher","first-page":"95023","DOI":"10.1371\/journal.pone.0095023","volume":"9","author":"M Burkovetskaya","year":"2014","unstructured":"Burkovetskaya, M. et al. Evidence for aberrant astrocyte hemichannel activity in juvenile neuronal ceroid lipofuscinosis (JNCL). PLoS One 9, 95023 (2014).","journal-title":"PLoS One"},{"key":"1132_CR167","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/jnc.12385","volume":"127","author":"J Xiong","year":"2013","unstructured":"Xiong, J. & Kielian, T. Microglia in juvenile neuronal ceroid lipofuscinosis are primed toward a pro-inflammatory phenotype. J. Neurochem. 127, 245\u2013258 (2013).","journal-title":"J. Neurochem."},{"key":"1132_CR168","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s42003-024-07057-w","volume":"7","author":"S Yasa","year":"2024","unstructured":"Yasa, S. et al. Loss of CLN3 in microglia leads to impaired lipid metabolism and myelin turnover. Commun. Biol. 7, 1373 (2024).","journal-title":"Commun. Biol."},{"key":"1132_CR169","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01996-x","volume":"28","author":"K Berve","year":"2020","unstructured":"Berve, K., West, B. L., Martini, R. & Groh, J. Sex- and region-biased depletion of microglia\/macrophages attenuates CLN1 disease in mice. J. Neuroinflammation. 28, 323 (2020).","journal-title":"J. Neuroinflammation."},{"key":"1132_CR170","doi-asserted-by":"publisher","first-page":"15575","DOI":"10.1523\/JNEUROSCI.3579-11.2011","volume":"26","author":"SL Macauley","year":"2011","unstructured":"Macauley, S. L., Pekny, M. & Sands, M. S. The role of attenuated astrocyte activation in infantile neuronal ceroid lipofuscinosis. J. Neurosci. 26, 15575\u201315585 (2011).","journal-title":"J. Neurosci."},{"key":"1132_CR171","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.3390\/ijms23105586","volume":"17","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Seizures in PPT1 Knock-in mice are associated with inflammatory activation of microglia. Int. J. Mol. Sci. 17, 5586 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1132_CR172","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/glia.22962","volume":"64","author":"J Groh","year":"2016","unstructured":"Groh, J. et al. Sialoadhesin promotes neuroinflammation-related disease progression in two mouse models of CLN disease. Glia 64, 792\u2013809 (2016).","journal-title":"Glia"},{"key":"1132_CR173","doi-asserted-by":"publisher","first-page":"fcab047","DOI":"10.1093\/braincomms\/fcab047","volume":"21","author":"J Groh","year":"2021","unstructured":"Groh, J., Berve, K. & Martini, R. Immune modulation attenuates infantile neuronal ceroid lipofuscinosis in mice before and after disease onset. Brain Commun. 21, fcab047 (2021).","journal-title":"Brain Commun."},{"key":"1132_CR174","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/BF00697751","volume":"11","author":"M Haltia","year":"1973","unstructured":"Haltia, M., Rapola, J. & Santavuori, P. Infantile type of so-called neuronal ceroid-lipofuscinosis. Histological and electron microscopic studies. Acta Neuropathol. 11, 157\u2013170 (1973).","journal-title":"Acta Neuropathol."},{"key":"1132_CR175","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/brain\/96.4.833","volume":"96","author":"J Rapola","year":"1973","unstructured":"Rapola, J. & Haltia, M. Cytoplasmic inclusions in the vermiform appendix and skeletal muscle in two types of so-called neuronal ceroid-lipofuscinosis. Brain 96, 833\u2013840 (1973).","journal-title":"Brain"},{"key":"1132_CR176","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2350\/07-03-0242.1","volume":"11","author":"N Galvin","year":"2008","unstructured":"Galvin, N. et al. A murine model of infantile neuronal ceroid lipofuscinosis-ultrastructural evaluation of storage in the central nervous system and viscera. Pediatr. Dev. Pathol. 11, 185\u2013192 (2008).","journal-title":"Pediatr. Dev. Pathol."},{"key":"1132_CR177","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/gt.2017.4","volume":"24","author":"ML Katz","year":"2017","unstructured":"Katz, M. L. et al. Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression. Gene Ther. 24, 215\u2013223 (2017).","journal-title":"Gene Ther."},{"key":"1132_CR178","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/WNL.0b013e31821435bd","volume":"76","author":"JR Ostergaard","year":"2011","unstructured":"Ostergaard, J. R., Rasmussen, T. B. & M\u00f8lgaard, H. Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology 76, 1245\u20131251 (2011).","journal-title":"Neurology"},{"key":"1132_CR179","doi-asserted-by":"publisher","first-page":"165643","DOI":"10.1016\/j.bbadis.2019.165643","volume":"1866","author":"K Rietdorf","year":"2020","unstructured":"Rietdorf, K. et al. Cardiac pathology in neuronal ceroid lipofuscinoses (NCL): more than a mere co-morbidity. Biochim. Biophys. Acta Mol. Basis Dis. 1866, 165643 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1132_CR180","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.autneu.2018.07.003","volume":"214","author":"JR Ostergaard","year":"2018","unstructured":"Ostergaard, J. R. Paroxysmal sympathetic hyperactivity in juvenile neuronal ceroid lipofuscinosis (Batten disease). Auton. Neurosci. 214, 15\u201318 (2018).","journal-title":"Auton. Neurosci."},{"key":"1132_CR181","doi-asserted-by":"publisher","first-page":"846240","DOI":"10.3389\/fneur.2022.846240","volume":"13","author":"MM Handrup","year":"2022","unstructured":"Handrup, M. M., M\u00f8lgaard, H., Andersen, B. N. & Ostergaard, J. R. Pacemaker implantation in juvenile neuronal ceroid lipofuscinosis (CLN3)-a long-term follow-up study. Front. Neurol. 13, 846240 (2022).","journal-title":"Front. Neurol."},{"key":"1132_CR182","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03336-1","volume":"19","author":"C Baekmann","year":"2024","unstructured":"Baekmann, C. et al. Insight of autonomic dysfunction in CLN3 disease: a study on episodes resembling paroxysmal sympathetic hyperactivity (PSH). Orphanet J. Rare Dis. 19, 374 (2024).","journal-title":"Orphanet J. Rare Dis."},{"key":"1132_CR183","doi-asserted-by":"publisher","first-page":"1059082","DOI":"10.3389\/fpsyt.2023.1059082","volume":"14","author":"JR Ostergaard","year":"2023","unstructured":"Ostergaard, J. R. Etiology of anxious and fearful behavior in juvenile neuronal ceroid lipofuscinosis (CLN3 disease). Front. Psychiatry 14, 1059082 (2023).","journal-title":"Front. Psychiatry"},{"key":"1132_CR184","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1097\/AJP.0000000000000192","volume":"31","author":"CC Barney","year":"2015","unstructured":"Barney, C. C., Hoch, J., Byiers, B., Dimian, A. & Symons, F. J. A case-controlled investigation of pain experience and sensory function in neuronal ceroid lipofuscinosis. Clin. J. Pain. 31, 998\u20131003 (2015).","journal-title":"Clin. J. Pain."},{"key":"1132_CR185","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1053\/ejpn.2000.0457","volume":"5","author":"MK Mannerkoski","year":"2001","unstructured":"Mannerkoski, M. K., Heiskala, H. J., Santavuori, P. R. & Pouttu, J. A. Transdermal fentanyl therapy for pains in children with infantile neuronal ceroid lipofuscinosis. Eur. J. Paediatr. Neurol. 5, 175\u2013177 (2001).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"1132_CR186","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00710255","volume":"16","author":"P Santavuori","year":"1993","unstructured":"Santavuori, P. et al. Psychological symptoms and sleep disturbances in neuronal ceroid-lipofuscinoses (NCL). J. Inher. Metab. Dis. 16, 245\u2013248 (1993).","journal-title":"J. Inher. Metab. Dis."},{"key":"1132_CR187","doi-asserted-by":"publisher","first-page":"105952","DOI":"10.1016\/j.nbd.2022.105952","volume":"176","author":"M Bosch-Queralt","year":"2023","unstructured":"Bosch-Queralt, M., Fledrich, R. & Stassart, R. M. Schwann cell functions in peripheral nerve development and repair. Neurobiol. Dis. 176, 105952 (2023).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR188","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/jnr.24231","volume":"96","author":"KB Santosa","year":"2018","unstructured":"Santosa, K. B., Keane, A. M., Jablonka-Shariff, A., Vannucci, B. & Snyder-Warwick, A. K. Clinical relevance of terminal Schwann cells: an overlooked component of the neuromuscular junction. J. Neurosci. Res. 96, 1125\u20131135 (2018).","journal-title":"J. Neurosci. Res."},{"key":"1132_CR189","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.tins.2024.03.007","volume":"47","author":"RL Hastings","year":"2024","unstructured":"Hastings, R. L. & Valdez, G. Origin, identity, and function of terminal Schwann cells. Trends Neurosci. 47, 432\u2013446 (2024).","journal-title":"Trends Neurosci."},{"key":"1132_CR190","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1126\/scitranslmed.adj1445","volume":"17","author":"EA Zi\u00f3\u0142kowska","year":"2025","unstructured":"Zi\u00f3\u0142kowska, E. A. et al. Gene therapy prevents bowel dysmotility, enteric neuron degeneration and extends survival in lysosomal storage disorder mouse models. Sci. Transl. Med. 17, 1445 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1132_CR191","doi-asserted-by":"publisher","unstructured":"Zi\u00f3\u0142kowska, E. A. et al. Enteric nervous system degeneration in human and murine CLN3 disease, is ameliorated by gene therapy in mice. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.01.29.635518 (2025).","DOI":"10.1101\/2025.01.29.635518"},{"key":"1132_CR192","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.brainresbull.2012.03.003","volume":"1","author":"JJ Shacka","year":"2012","unstructured":"Shacka, J. J. Mouse models of neuronal ceroid lipofuscinoses: useful pre-clinical tools to delineate disease pathophysiology and validate therapeutics. Brain Res. Bull. 1, 43\u201357 (2012).","journal-title":"Brain Res. Bull."},{"key":"1132_CR193","doi-asserted-by":"publisher","first-page":"165559","DOI":"10.1016\/j.bbadis.2019.165559","volume":"1","author":"CJ Minnis","year":"2020","unstructured":"Minnis, C. J., Thornton, C. D., FitzPatrick, L. M. & McKay, T. R. Cellular models of Batten disease. Biochim. Biophys. Acta Mol. Basis Dis. 1, 165559 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1132_CR194","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jnr.25147","volume":"101","author":"G Nittari","year":"2023","unstructured":"Nittari, G. et al. Batten disease through different in vivo and in vitro models: a review. J. Neurosci. Res. 101, 298\u2013315 (2023).","journal-title":"J. Neurosci. Res."},{"key":"1132_CR195","doi-asserted-by":"publisher","first-page":"103563","DOI":"10.1016\/j.scr.2024.103563","volume":"81","author":"E Dwojak","year":"2024","unstructured":"Dwojak, E. et al. Six induced pluripotent stem cell lines from fibroblasts of individuals with CLN3-related conditions. Stem Cell Res. 81, 103563 (2024).","journal-title":"Stem Cell Res."},{"key":"1132_CR196","doi-asserted-by":"publisher","unstructured":"Otero, M. G. et al. Cellular modeling of CLN6 with IPSC-derived neurons and glia. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.01.29.577876 (2024).","DOI":"10.1101\/2024.01.29.577876"},{"key":"1132_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2023.103291","volume":"74","author":"M Ofrim","year":"2024","unstructured":"Ofrim, M. et al. Characterization of two human induced pluripotent stem cell lines derived from Batten disease patient fibroblasts harbouring CLN5 mutations. Stem Cell Res. 74, 103291 (2024).","journal-title":"Stem Cell Res."},{"key":"1132_CR198","doi-asserted-by":"publisher","first-page":"105891","DOI":"10.1016\/j.nbd.2022.105891","volume":"175","author":"P Bossolasco","year":"2022","unstructured":"Bossolasco, P. et al. GRN-\/- iPSC-derived cortical neurons recapitulate the pathological findings of both frontotemporal lobar degeneration and neuronal ceroidolipofuscinosis. Neurobiol. Dis. 175, 105891 (2022).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR199","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/ijms18050955","volume":"1","author":"K Uusi-Rauva","year":"2017","unstructured":"Uusi-Rauva, K. et al. Induced pluripotent stem cells derived from a CLN5 patient manifest phenotypic characteristics of neuronal ceroid lipofuscinoses. Int. J. Mol. Sci. 1, 955 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"1132_CR200","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1093\/hmg\/ddt596","volume":"23","author":"X Lojewski","year":"2014","unstructured":"Lojewski, X. et al. Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway. Hum. Mol. Genet. 23, 2005\u20132022 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"1132_CR201","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1021\/acsptsci.0c00077","volume":"3","author":"N Kinarivala","year":"2020","unstructured":"Kinarivala, N. et al. An iPSC-derived neuron model of CLN3 disease facilitates small molecule phenotypic screening. ACS Pharmacol. Transl. Sci. 3, 931\u2013947 (2020).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"1132_CR202","doi-asserted-by":"publisher","first-page":"9032","DOI":"10.1073\/pnas.1917675117","volume":"21","author":"CR Mikulka","year":"2020","unstructured":"Mikulka, C. R. et al. Cell-autonomous expression of the acid hydrolase galactocerebrosidase. Proc. Natl Acad. Sci. USA 21, 9032\u20139041 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1132_CR203","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s00335-017-9687-6","volume":"28","author":"SL Eaton","year":"2017","unstructured":"Eaton, S. L. & Wishart, T. M. Bridging the gap: large animal models in neurodegenerative research. Mamm. Genome 28, 324\u2013337 (2017).","journal-title":"Mamm. Genome"},{"key":"1132_CR204","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.nbd.2017.08.017","volume":"108","author":"ML Katz","year":"2017","unstructured":"Katz, M. L. et al. Canine neuronal ceroid lipofuscinoses: promising models for preclinical testing of therapeutic interventions. Neurobiol. Dis. 108, 277\u2013287 (2017).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR205","doi-asserted-by":"publisher","first-page":"831838","DOI":"10.3389\/fvets.2022.831838","volume":"15","author":"SJ Murray","year":"2022","unstructured":"Murray, S. J. & Mitchell, N. L. The translational benefits of sheep as large animal models of human neurological disorders. Front. Vet. Sci. 15, 831838 (2022).","journal-title":"Front. Vet. Sci."},{"key":"1132_CR206","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/dneu.22918","volume":"83","author":"NL Mitchell","year":"2023","unstructured":"Mitchell, N. L., Russell, K. N., Barrell, G. K., Tammen, I. & Palmer, D. N. Characterization of neuropathology in ovine CLN5 and CLN6 neuronal ceroid lipofuscinoses (Batten disease). Dev. Neurobiol. 83, 127\u2013142 (2023).","journal-title":"Dev. Neurobiol."},{"key":"1132_CR207","first-page":"fcac339","volume":"2","author":"SJ Murray","year":"2023","unstructured":"Murray, S. J. et al. Progressive MRI brain volume changes in ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinosis. Brain Commun. 2, fcac339 (2023).","journal-title":"Brain Commun."},{"key":"1132_CR208","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1750-3639.2006.00002.x","volume":"16","author":"GW Kay","year":"2006","unstructured":"Kay, G. W., Palmer, D. N., Rezaie, P. & Cooper, J. D. Activation of non-neuronal cells within the prenatal developing brain of sheep with neuronal ceroid lipofuscinosis. Brain Pathol. 16, 110\u2013116 (2006).","journal-title":"Brain Pathol."},{"key":"1132_CR209","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.nbd.2005.01.025","volume":"20","author":"MJ Oswald","year":"2005","unstructured":"Oswald, M. J. et al. Glial activation spreads from specific cerebral foci and precedes neurodegeneration in presymptomatic ovine neuronal ceroid lipofuscinosis (CLN6). Neurobiol. Dis. 20, 49\u201363 (2005).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR210","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.401","volume":"9","author":"IS Amorim","year":"2015","unstructured":"Amorim, I. S. et al. Molecular neuropathology of the synapse in sheep with CLN5 Batten disease. Brain Behav. 9, e00401 (2015).","journal-title":"Brain Behav."},{"key":"1132_CR211","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.nbd.2007.09.006","volume":"29","author":"T Frugier","year":"2008","unstructured":"Frugier, T. et al. A new large animal model of CLN5 neuronal ceroid lipofuscinosis in Borderdale sheep is caused by a nucleotide substitution at a consensus splice site (c.571+1G>A) leading to excision of exon 3. Neurobiol. Dis. 29, 306\u2013315 (2008).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR212","doi-asserted-by":"publisher","first-page":"114381","DOI":"10.1016\/j.expneurol.2023.114381","volume":"363","author":"Y Munesue","year":"2023","unstructured":"Munesue, Y. et al. Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease. Exp. Neurol. 363, 114381 (2023).","journal-title":"Exp. Neurol."},{"key":"1132_CR213","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.nbd.2018.07.013","volume":"119","author":"JL McBride","year":"2018","unstructured":"McBride, J. L. et al. Discovery of a CLN7 model of Batten disease in non-human primates. Neurobiol. Dis. 119, 65\u201378 (2018).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR214","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s13311-022-01296-7","volume":"19","author":"VJ Swier","year":"2022","unstructured":"Swier, V. J. et al. A novel porcine model of CLN2 Batten disease that recapitulates patient phenotypes. Neurotherapeutics 19, 1905\u20131919 (2022).","journal-title":"Neurotherapeutics"},{"key":"1132_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32071-z","volume":"29","author":"K Knoernschild","year":"2023","unstructured":"Knoernschild, K. et al. Magnetic resonance brain volumetry biomarkers of CLN2 Batten disease identified with miniswine model. Sci. Rep. 29, 5146 (2023).","journal-title":"Sci. Rep."},{"key":"1132_CR216","doi-asserted-by":"publisher","first-page":"dmm050038","DOI":"10.1242\/dmm.050038","volume":"1","author":"VJ Swier","year":"2023","unstructured":"Swier, V. J. et al. A novel porcine model of CLN3 Batten disease recapitulates clinical phenotypes. Dis. Model. Mech. 1, dmm050038 (2023).","journal-title":"Dis. Model. Mech."},{"key":"1132_CR217","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45859-9","volume":"9","author":"SL Eaton","year":"2019","unstructured":"Eaton, S. L. et al. CRISPR\/Cas9 mediated generation of an ovine model for infantile neuronal ceroid lipofuscinosis (CLN1 disease). Sci. Rep. 9, 9891 (2019).","journal-title":"Sci. Rep."},{"key":"1132_CR218","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.3390\/cells11172641","volume":"11","author":"SL Eaton","year":"2022","unstructured":"Eaton, S. L. et al. Modelling neurological diseases in large animals: criteria for model selection and clinical assessment. Cells 11, 2641 (2022).","journal-title":"Cells"},{"key":"1132_CR219","first-page":"102020","volume":"31","author":"K Iwan","year":"2020","unstructured":"Iwan, K. et al. Urine proteomics analysis of patients with neuronal ceroid lipofuscinoses. iScience 31, 102020 (2020).","journal-title":"iScience"},{"key":"1132_CR220","doi-asserted-by":"publisher","first-page":"117727192211077","DOI":"10.1177\/11772719221107765","volume":"17","author":"JJ Brudvig","year":"2022","unstructured":"Brudvig, J. J. et al. Glycerophosphoinositol is elevated in blood samples from CLN3\u0394ex7-8 pigs, Cln3\u0394ex7-8 mice, and CLN3-affected individuals. Biomark. Insights 17, 11772719221107765 (2022).","journal-title":"Biomark. Insights"},{"key":"1132_CR221","doi-asserted-by":"publisher","first-page":"29729","DOI":"10.1371\/journal.pone.0029729","volume":"7","author":"M Velinov","year":"2012","unstructured":"Velinov, M. et al. Mutations in the gene DNAJC5 cause autosomal dominant Kufs disease in a proportion of cases: study of the Parry family and 8 other families. PLoS One 7, 29729 (2012).","journal-title":"PLoS One"},{"key":"1132_CR222","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"22","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N. Engl. J. Med. 22, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1132_CR223","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1212\/WNL.0b013e31828f180e","volume":"23","author":"Z Gan-Or","year":"2013","unstructured":"Gan-Or, Z. et al. The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 23, 1606\u20131610 (2013).","journal-title":"Neurology"},{"key":"1132_CR224","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/mds.24886","volume":"27","author":"H Michelakakis","year":"2012","unstructured":"Michelakakis, H. et al. Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson\u2019s disease. Mov. Disord. 27, 400\u2013405 (2012).","journal-title":"Mov. Disord."},{"key":"1132_CR225","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fnagi.2018.00402","volume":"13","author":"G Li","year":"2018","unstructured":"Li, G. et al. Association of GALC, ZNF184, IL1R2 and ELOVL7 with Parkinson\u2019s disease in southern Chinese. Front. Aging Neurosci. 13, 402 (2018).","journal-title":"Front. Aging Neurosci."},{"key":"1132_CR226","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/jmg-2023-109219","volume":"21","author":"D Lopergolo","year":"2024","unstructured":"Lopergolo, D. et al. Familial Alzheimer\u2019s disease associated with heterozygous NPC1 mutation. J. Med. Genet. 21, 332\u2013339 (2024).","journal-title":"J. Med. Genet."},{"key":"1132_CR227","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-020-00649-8","volume":"6","author":"CN Suire","year":"2020","unstructured":"Suire, C. N. et al. Cathepsin D regulates cerebral A\u03b242\/40 ratios via differential degradation of A\u03b242 and A\u03b240. Alzheimers Res. Ther. 6, 80 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"1132_CR228","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/aje\/kwh069","volume":"15","author":"C Ntais","year":"2004","unstructured":"Ntais, C., Polycarpou, A. & Ioannidis, J. P. Meta-analysis of the association of the cathepsin D Ala224Val gene polymorphism with the risk of Alzheimer\u2019s disease: a HuGE gene-disease association review. Am. J. Epidemiol. 15, 527\u2013536 (2004).","journal-title":"Am. J. Epidemiol."},{"key":"1132_CR229","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1073\/pnas.1719808115","volume":"13","author":"S Sol\u00e9-Dom\u00e8nech","year":"2018","unstructured":"Sol\u00e9-Dom\u00e8nech, S. et al. Lysosomal enzyme tripeptidyl peptidase 1 destabilizes fibrillar A\u03b2 by multiple endoproteolytic cleavages within the \u03b2-sheet domain. Proc. Natl Acad. Sci. Usa. 13, 1493\u20131498 (2018).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"1132_CR230","doi-asserted-by":"publisher","unstructured":"Benitez, B. A. et al. Haploinsufficiency of lysosomal enzyme genes in Alzheimer\u2019s disease. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.11.16.623962 (2024).","DOI":"10.1101\/2024.11.16.623962"},{"key":"1132_CR231","doi-asserted-by":"publisher","first-page":"13566","DOI":"10.1073\/pnas.251485198","volume":"98","author":"P Gupta","year":"2001","unstructured":"Gupta, P. et al. Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice. Proc. Natl Acad. Sci. USA 98, 13566\u201313571 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1132_CR232","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/hmg\/ddu428","volume":"24","author":"JN Miller","year":"2015","unstructured":"Miller, J. N., Kov\u00e1cs, A. D. & Pearce, D. A. The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy. Hum. Mol. Genet. 24, 185\u2013196 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"1132_CR233","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.nbd.2004.08.013","volume":"18","author":"A Jalanko","year":"2005","unstructured":"Jalanko, A. et al. Mice with Ppt1Deltaex4 mutation replicate the INCL phenotype and show an inflammation-associated loss of interneurons. Neurobiol. Dis. 18, 226\u2013241 (2005).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR234","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ymgme.2010.04.009","volume":"100","author":"DN Sanders","year":"2010","unstructured":"Sanders, D. N. et al. A mutation in canine PPT1 causes early onset neuronal ceroid lipofuscinosis in a Dachshund. Mol. Genet. Metab. 100, 349\u2013356 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"1132_CR235","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/jvim.14632","volume":"31","author":"A Kolicheski","year":"2017","unstructured":"Kolicheski, A. et al. Homozygous PPT1 splice donor mutation in a cane corso dog with neuronal ceroid lipofuscinosis. J. Vet. Intern. Med. 31, 149\u2013157 (2017).","journal-title":"J. Vet. Intern. Med."},{"key":"1132_CR236","doi-asserted-by":"publisher","first-page":"9117","DOI":"10.1523\/JNEUROSCI.2729-04.2004","volume":"24","author":"DE Sleat","year":"2004","unstructured":"Sleat, D. E. et al. A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration. J. Neurosci. 24, 9117\u20139126 (2004).","journal-title":"J. Neurosci."},{"key":"1132_CR237","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176526","volume":"12","author":"RD Geraets","year":"2017","unstructured":"Geraets, R. D. et al. A tailored mouse model of CLN2 disease: a nonsense mutant for testing personalized therapies. PLoS One 12, e0176526 (2017).","journal-title":"PLoS One"},{"key":"1132_CR238","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ymgme.2006.02.016","volume":"89","author":"T Awano","year":"2006","unstructured":"Awano, T. et al. A frame shift mutation in canine TPP1 (the ortholog of human CLN2) in a juvenile Dachshund with neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 89, 254\u2013260 (2006).","journal-title":"Mol. Genet. Metab."},{"key":"1132_CR239","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/brain\/awt043","volume":"136","author":"F Mahmood","year":"2013","unstructured":"Mahmood, F. et al. A zebrafish model of CLN2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation. Brain 136, 1488\u20131507 (2013).","journal-title":"Brain"},{"key":"1132_CR240","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1006\/nbdi.1999.0267","volume":"6","author":"HM Mitchison","year":"1999","unstructured":"Mitchison, H. M. et al. Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten mouse model consortium [corrected]. Neurobiol. Dis. 6, 321\u2013334 (1999).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR241","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/(SICI)1097-4547(19990815)57:4<551::AID-JNR15>3.0.CO;2-R","volume":"57","author":"ML Katz","year":"1999","unstructured":"Katz, M. L. et al. A mouse gene knockout model for juvenile ceroid-lipofuscinosis (Batten disease). J. Neurosci. Res. 57, 551\u2013556 (1999).","journal-title":"J. Neurosci. Res."},{"key":"1132_CR242","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1093\/hmg\/11.22.2709","volume":"11","author":"SL Cotman","year":"2002","unstructured":"Cotman, S. L. et al. Cln3(Deltaex7\/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum. Mol. Genet. 11, 2709\u20132721 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"1132_CR243","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202302057","volume":"7","author":"U Heins-Marroquin","year":"2024","unstructured":"Heins-Marroquin, U. et al. CLN3 deficiency leads to neurological and metabolic perturbations during early development. Life Sci. Alliance 7, e202302057 (2024).","journal-title":"Life Sci. Alliance"},{"key":"1132_CR244","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157365","volume":"11","author":"K Wager","year":"2016","unstructured":"Wager, K. et al. Neurodegeneration and epilepsy in a zebrafish model of CLN3 disease (Batten disease). PLoS One 11, e0157365 (2016).","journal-title":"PLoS One"},{"key":"1132_CR245","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ads3393","volume":"11","author":"S L\u00f3pez-Begines","year":"2025","unstructured":"L\u00f3pez-Begines, S. et al. Neuronal lipofuscinosis caused by Kufs disease\/CLN4 DNAJC5 mutations but not by a CSP\u03b1\/DNAJC5 deficiency. Sci. Adv. 11, eads3393 (2025).","journal-title":"Sci. Adv."},{"key":"1132_CR246","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ygeno.2005.06.005","volume":"86","author":"SA Melville","year":"2005","unstructured":"Melville, S. A. et al. A mutation in canine CLN5 causes neuronal ceroid lipofuscinosis in border collie dogs. Genomics 86, 287\u2013294 (2005).","journal-title":"Genomics"},{"key":"1132_CR247","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/jvim.13971","volume":"30","author":"A Kolicheski","year":"2016","unstructured":"Kolicheski, A. et al. Australian cattle dogs with neuronal ceroid lipofuscinosis are homozygous for a CLN5 nonsense mutation previously identified in border collies. J. Vet. Intern. Med. 30, 1149\u20131158 (2016).","journal-title":"J. Vet. Intern. Med."},{"key":"1132_CR248","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ymgme.2015.04.001","volume":"115","author":"D Gilliam","year":"2015","unstructured":"Gilliam, D. et al. Golden retriever dogs with neuronal ceroid lipofuscinosis have a two-base-pair deletion and frameshift in CLN5. Mol. Genet. Metab. 115, 101\u2013109 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"1132_CR249","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.bbadis.2006.07.008","volume":"1762","author":"PJ Houweling","year":"2006","unstructured":"Houweling, P. J. et al. Neuronal ceroid lipofuscinosis in Devon cattle is caused by a single base duplication (c.662dupG) in the bovine CLN5 gene. Biochim. Biophys. Acta 1762, 890\u2013897 (2006).","journal-title":"Biochim. Biophys. Acta"},{"key":"1132_CR250","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/(SICI)1096-8628(19980526)77:4<289::AID-AJMG8>3.0.CO;2-I","volume":"77","author":"RT Bronson","year":"1998","unstructured":"Bronson, R. T. et al. Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9. Am. J. Med. Genet. 77, 289\u2013297 (1998).","journal-title":"Am. J. Med. Genet."},{"key":"1132_CR251","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2990.1989.tb01236.x","volume":"15","author":"RD Jolly","year":"1989","unstructured":"Jolly, R. D. et al. Ceroid-lipofuscinosis (Batten\u2019s disease): pathogenesis and sequential neuropathological changes in the ovine model. Neuropathol. Appl. Neurobiol. 15, 371\u2013383 (1989).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"1132_CR252","volume":"2011","author":"ML Katz","year":"2011","unstructured":"Katz, M. L. et al. O\u2019Brien DP. A missense mutation in canine CLN6 in an Australian shepherd with neuronal ceroid lipofuscinosis. J. Biomed. Biotechnol. 2011, 198042 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"1132_CR253","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/hmg\/ddv615","volume":"25","author":"L Brandenstein","year":"2016","unstructured":"Brandenstein, L., Schweizer, M., Sedlacik, J., Fiehler, J. & Storch, S. Lysosomal dysfunction and impaired autophagy in a novel mouse model deficient for the lysosomal membrane protein Cln7. Hum. Mol. Genet. 25, 777\u2013791 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"1132_CR254","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ymgme.2016.05.008","volume":"118","author":"A Ashwini","year":"2016","unstructured":"Ashwini, A. et al. Neuronal ceroid lipofuscinosis associated with an MFSD8 mutation in Chihuahuas. Mol. Genet. Metab. 118, 326\u2013332 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"1132_CR255","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jnr.23710","volume":"94","author":"KM Faller","year":"2016","unstructured":"Faller, K. M. et al. The Chihuahua dog: a new animal model for neuronal ceroid lipofuscinosis CLN7 disease? J. Neurosci. Res. 94, 339\u2013347 (2016).","journal-title":"J. Neurosci. Res."},{"key":"1132_CR256","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.bbrc.2004.12.038","volume":"327","author":"ML Katz","year":"2005","unstructured":"Katz, M. L. et al. A mutation in the CLN8 gene in English Setter dogs with neuronal ceroid-lipofuscinosis. Biochem. Biophys. Res. Commun. 327, 541\u2013547 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1132_CR257","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ymgme.2014.05.014","volume":"112","author":"J Guo","year":"2014","unstructured":"Guo, J. et al. A CLN8 nonsense mutation in the whole genome sequence of a mixed breed dog with neuronal ceroid lipofuscinosis and Australian shepherd ancestry. Mol. Genet. Metab. 112, 302\u2013309 (2014).","journal-title":"Mol. Genet. Metab."},{"key":"1132_CR258","volume":"21","author":"J Guo","year":"2019","unstructured":"Guo, J. et al. Neuronal ceroid lipofuscinosis in a German shorthaired pointer associated with a previously reported CLN8 nonsense variant. Mol. Genet. Metab. Rep. 21, 100521 (2019).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"1132_CR259","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1002\/j.1460-2075.1995.tb00029.x","volume":"14","author":"P Saftig","year":"1995","unstructured":"Saftig, P. et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 14, 3599\u20133608 (1995).","journal-title":"EMBO J."},{"key":"1132_CR260","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ymgme.2005.11.005","volume":"87","author":"T Awano","year":"2006","unstructured":"Awano, T. et al. A mutation in the cathepsin D gene (CTSD) in American bulldogs with neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 87, 341\u2013348 (2006).","journal-title":"Mol. Genet. Metab."},{"key":"1132_CR261","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1093\/emboj\/19.12.2786","volume":"19","author":"J Tyynel\u00e4","year":"2000","unstructured":"Tyynel\u00e4, J. et al. A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration. EMBO J. 19, 2786\u20132792 (2000).","journal-title":"EMBO J."},{"key":"1132_CR262","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.brainres.2014.09.023","volume":"1588","author":"BP Hafler","year":"2014","unstructured":"Hafler, B. P., Klein, Z. A., Jimmy Zhou, Z. & Strittmatter, S. M. Progressive retinal degeneration and accumulation of autofluorescent lipopigments in progranulin deficient mice. Brain Res. 1588, 168\u2013174 (2014).","journal-title":"Brain Res."},{"key":"1132_CR263","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1093\/hmg\/ddt057","volume":"22","author":"PJ Schultheis","year":"2013","unstructured":"Schultheis, P. J. et al. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited \u03b1-synuclein accumulation and age-dependent sensorimotor deficits. Hum. Mol. Genet. 22, 2067\u20132082 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"1132_CR264","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.nbd.2011.02.009","volume":"42","author":"FH Farias","year":"2011","unstructured":"Farias, F. H. et al. A truncating mutation in ATP13A2 is responsible for adult-onset neuronal ceroid lipofuscinosis in Tibetan terriers. Neurobiol. Dis. 42, 468\u2013474 (2011).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR265","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.049642","volume":"15","author":"JH Liang","year":"2022","unstructured":"Liang, J. H. et al. Kctd7 deficiency induces myoclonic seizures associated with purkinje cell death and microvascular defects. Dis. Model. Mech. 15, dmm049642 (2022).","journal-title":"Dis. Model. Mech."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01132-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01132-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01132-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:02:43Z","timestamp":1761692563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01132-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":265,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1038\/s41582-025-01132-4","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"8 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.D.C. has received research support from Abeona Therapeutics Inc., BioMarin Pharmaceutical Inc., Neurogene, and REGENXBIO Inc. and is a consultant for JCR Pharmaceuticals. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}